CD4 and neoplasm: Mice that received PTSO-treated hPBMCs exhibited an increased infiltration of total CD45+ immune cells within the tumor that was associated with a significant enrichment of CD3+CD4+ Th cells and CD3−CD56+ NK cells (Figure 6B), thus suggesting enhanced anti-tumor immune activity within the tumor microenvironment.